Identifying High-Risk NASH Patients: What We Know so Far

Marten Schulz, Frank Tacke Department of Hepatology and Gastroenterology, Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum (CVK) Und Campus Charité Mitte (CCM), Berlin, GermanyCorrespondence: Marten Schulz Email marten.schulz@charite.deAbstract: Steatosis is...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Schulz M, Tacke F
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	nafld fibrosis cirrhosis hepatocellular carcinoma elastography liver-stiffness measurement Diseases of the digestive system. Gastroenterology RC799-869
Acceso en línea:	https://doaj.org/article/4ad489856c48403ba962900db6201b89
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4ad489856c48403ba962900db6201b89
record_format	dspace
spelling	oai:doaj.org-article:4ad489856c48403ba962900db6201b892021-12-02T10:06:59ZIdentifying High-Risk NASH Patients: What We Know so Far1179-1535https://doaj.org/article/4ad489856c48403ba962900db6201b892020-08-01T00:00:00Zhttps://www.dovepress.com/identifying-high-risk-nash-patients-what-we-know-so-far-peer-reviewed-article-HMERhttps://doaj.org/toc/1179-1535Marten Schulz, Frank Tacke Department of Hepatology and Gastroenterology, Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum (CVK) Und Campus Charité Mitte (CCM), Berlin, GermanyCorrespondence: Marten Schulz Email marten.schulz@charite.deAbstract: Steatosis is a condition of hepatic fat overload that is associated with overweight and the metabolic syndrome. Nonalcoholic fatty liver disease (NAFLD) has become the most common liver disease with a global impact on healthcare. A proportion of NAFLD patients develops nonalcoholic steatohepatitis (NASH), liver fibrosis, cirrhosis or hepatocellular carcinoma (HCC). Identifying patients at risk for potentially life-threatening complications is crucial in their prevention, surveillance and treatment. In addition to hepatic disease progression (cirrhosis, portal hypertension, HCC), NAFLD patients are also at risk of cardiovascular and metabolic diseases as well as extrahepatic malignancies. Liver fibrosis is related to morbidity and mortality in NASH patients, and biomarkers, imaging techniques (ultrasound, elastography, MRI) as well as liver biopsy help in diagnosing fibrosis. In this review, we discuss the tools for identifying patients at risk and their reasonable application in clinical routine in order to stratify prevention and treatment of this emerging disease.Keywords: NAFLD, fibrosis, cirrhosis, hepatocellular carcinoma, elastography, liver-stiffness measurementSchulz MTacke FDove Medical Pressarticlenafldfibrosiscirrhosishepatocellular carcinomaelastographyliver-stiffness measurementDiseases of the digestive system. GastroenterologyRC799-869ENHepatic Medicine: Evidence and Research, Vol Volume 12, Pp 125-138 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	nafld fibrosis cirrhosis hepatocellular carcinoma elastography liver-stiffness measurement Diseases of the digestive system. Gastroenterology RC799-869
spellingShingle	nafld fibrosis cirrhosis hepatocellular carcinoma elastography liver-stiffness measurement Diseases of the digestive system. Gastroenterology RC799-869 Schulz M Tacke F Identifying High-Risk NASH Patients: What We Know so Far
description	Marten Schulz, Frank Tacke Department of Hepatology and Gastroenterology, Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum (CVK) Und Campus Charité Mitte (CCM), Berlin, GermanyCorrespondence: Marten Schulz Email marten.schulz@charite.deAbstract: Steatosis is a condition of hepatic fat overload that is associated with overweight and the metabolic syndrome. Nonalcoholic fatty liver disease (NAFLD) has become the most common liver disease with a global impact on healthcare. A proportion of NAFLD patients develops nonalcoholic steatohepatitis (NASH), liver fibrosis, cirrhosis or hepatocellular carcinoma (HCC). Identifying patients at risk for potentially life-threatening complications is crucial in their prevention, surveillance and treatment. In addition to hepatic disease progression (cirrhosis, portal hypertension, HCC), NAFLD patients are also at risk of cardiovascular and metabolic diseases as well as extrahepatic malignancies. Liver fibrosis is related to morbidity and mortality in NASH patients, and biomarkers, imaging techniques (ultrasound, elastography, MRI) as well as liver biopsy help in diagnosing fibrosis. In this review, we discuss the tools for identifying patients at risk and their reasonable application in clinical routine in order to stratify prevention and treatment of this emerging disease.Keywords: NAFLD, fibrosis, cirrhosis, hepatocellular carcinoma, elastography, liver-stiffness measurement
format	article
author	Schulz M Tacke F
author_facet	Schulz M Tacke F
author_sort	Schulz M
title	Identifying High-Risk NASH Patients: What We Know so Far
title_short	Identifying High-Risk NASH Patients: What We Know so Far
title_full	Identifying High-Risk NASH Patients: What We Know so Far
title_fullStr	Identifying High-Risk NASH Patients: What We Know so Far
title_full_unstemmed	Identifying High-Risk NASH Patients: What We Know so Far
title_sort	identifying high-risk nash patients: what we know so far
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/4ad489856c48403ba962900db6201b89
work_keys_str_mv	AT schulzm identifyinghighrisknashpatientswhatweknowsofar AT tackef identifyinghighrisknashpatientswhatweknowsofar
_version_	1718397639000588288

Identifying High-Risk NASH Patients: What We Know so Far

Ejemplares similares